



Ministry of Health Malaysia

# **GUIDELINE FOR FACILITATED REGISTRATION PATHWAY**

Revision 1 (November 2023)

National Pharmaceutical Regulatory Agency  
Ministry of Health Malaysia

No.	Description of Amendment	Effective Date
1.	<b>Initial Publication</b>	<b>March 2019</b>
2.	<p><b>First Revision</b></p> <p>Summary of revision:</p> <p>i) The revised pathway includes registration schemes that may be considered for abbreviated and verification review as well as the inclusion of additional Drug Control Authority (DCA) reference agencies.</p> <p>ii) The scope is broadened to include generic medicines in addition to new drug products and biologics (including CGTP).</p> <p>iii) Eligibility criteria, documents required and the timeline for registration process are revised according to type of review.</p> <p>iv) Inclusion of dossier checklists and process flowcharts.</p>	<b>November 2023</b>

# Table of Contents

<b>ABBREVIATIONS</b> .....	1
<b>1. INTRODUCTION</b> .....	2
1.1 Background .....	2
1.2 Objectives .....	2
1.3 Scope .....	2
1.4 Review Pathways .....	3
<b>2. ELIGIBILITY CRITERIA:</b> .....	4
2.1 Abbreviated Review .....	4
2.1.1 WHO Collaborative Registration Procedure (CRP) .....	4
2.1.2 Products approved by the EMA and/or Health Canada and/or PMDA, Japan and/or Swissmedic, Switzerland and/or TGA, Australia and/or UK MHRA, and/or US FDA.....	4
2.2 Verification Review .....	5
2.2.1 ASEAN Joint Assessment (JA) procedure .....	5
<b>3. DOCUMENTS REQUIRED:</b> .....	5
3.1 Abbreviated Review .....	6
3.1.1 WHO Collaborative Registration Procedure (CRP) .....	6
3.1.2 Products approved by the EMA and/or Health Canada and/or PMDA, Japan and/or Swissmedic, Switzerland and/or TGA, Australia and/or UK MHRA, and/or US FDA.....	7
3.2 Verification review.....	9
3.2.1 ASEAN Joint Assessment (JA) Procedure .....	9
<b>4. TIMELINE FOR REGISTRATION PROCESS</b> .....	9
<b>5. DRUG CONTROL AUTHORITY RIGHTS</b> .....	10
<b>6. REFERENCES</b> .....	10
<b>7. ANNEXES</b> .....	11
7.1 Annex 1: Declaration statement by the applicant .....	11
7.2 Annex 2a: Dossier Checklist for FRP (Generic /Hybrid).....	12
7.3 Annex 2b: Dossier Checklist for FRP (New Chemical Entity/Biologic).....	17
7.4 Annex 3a: Process Flowchart for WHO SRA/WLA CRP .....	28
7.5 Annex 3b: Process Flowchart for WHO PQ CRP .....	29
7.6 Annex 3c: Process Flowchart for Products approved by the EMA and/or Health Canada and/or PMDA, Japan and/or Swissmedic, Switzerland and/or TGA, Australia and/or UK MHRA, and/or US FDA .....	30
7.7 Annex 3d: Process Flowchart for ASEAN Joint Assessment .....	31

## ABBREVIATIONS

API	Active pharmaceutical ingredient
BE	Bioequivalence
CGTP	Cell and gene therapy products
CPP	Certificate of Pharmaceutical Product
CRP	Collaborative Registration Procedure
DCA	Drug Control Authority
DMF	Drug Master File
DRGD	Drug Registration Guidance Document
EMA	European Medicines Agency
FPP	Finished pharmaceutical product
FRP	Facilitated Registration Pathway
GMP	Good Manufacturing Practice
JA	Joint Assessment
NPRA	National Pharmaceutical Regulatory Agency
PI	Package Insert
PIL	Patient Information Leaflet
PMDA	Pharmaceuticals and Medical Devices Agency
PQP	Prequalification of Medicines Programme
PRH	Product Registration Holder
SPC	Summary of Product Characteristics
SRA	Stringent Regulatory Authority
TGA	Therapeutic Goods Administration
UK MHRA	United Kingdom Medicines and Healthcare products Regulatory Agency
US FDA	United States Food and Drug Administration
WLA	WHO Listed Authority

# GUIDELINE FOR FACILITATED REGISTRATION PATHWAY (FRP)

## 1. INTRODUCTION

### 1.1 Background

An effective regulatory system is an essential component of health system strengthening and contributes to better public health outcomes. In order to improve regulatory capacity and efficiency, the National Pharmaceutical Regulatory Agency (NPRA) published the first edition of the Facilitated Registration Pathway (FRP) guideline in 2019. The guideline is developed based on reliance concept.

The reliance mechanism is applied by leveraging the work performed by other regulatory bodies on the same products intended for the local market. This mechanism is initiated to reduce duplication of effort and enable NPRA to emphasize the risk-based approach in both pre and post-market authorization activities. Reliance procedures provide a more efficient review process and ultimately early access to pharmaceutical products in the market.

### 1.2 Objectives

This guidance document is intended to provide a transparent and consistent procedure in the utilization of the reliance approach.

The guideline describes the procedures, requirements for submitting the application to register a product via this pathway and serves as a **supplementary document to Drug Registration Guidance Document (DRGD)**. The applicant should refer to both documents before completing product registration application via QUEST system.

### 1.3 Scope

The scope of this guideline applies to new drug products, generic medicines and biologics including cell and gene therapy products (CGTPs).

The final decision for a product to be considered via FRP is subject to NPRA discretion. NPRA may decide based on the eligibility criteria stated in this guideline, which may include risk-benefit assessment, country priorities, public health needs, and other reasons or opportunities for reliance.

## 1.4 Review Pathways

The following review pathways will be used to assess products eligible to be submitted via FRP:

- i) Abbreviated review: A limited independent assessment of specific parts of the dossier, or submission for suitability of use under local conditions and regulatory requirements, while relying on prior assessment and inspection outcomes from a reference authority or trusted institution to inform the local decision.

OR

- ii) Verification review: Review of the sameness of the product dossier to ensure that the medical product is the same as the one that has been assessed by ASEAN Joint Assessment.

Both review pathways apply to products approved by either of the following procedures or regulatory agencies:

### Abbreviated Review

- i) WHO Collaborative Registration Procedure (CRP)\*
  - a) Products authorised by WHO Stringent Regulatory Authorities (SRAs)/ WHO Listed Authorities (WLA)
  - b) WHO prequalified medicines and vaccines
- ii) Products approved by any of the following regulatory agencies\*\*
  - a) European Medicines Agency (EMA)
  - b) Health Canada
  - c) Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  - d) Swissmedic, Switzerland
  - e) Therapeutic Goods Administration (TGA), Australia
  - f) United Kingdom Medicines and Healthcare products Regulatory Agency (UK MHRA)
  - g) United States Food and Drug Administration (US FDA)

### Verification Review

- i) ASEAN Joint Assessment (JA) procedure\*

\*Registration applications submitted to the NPRA under the FRP pathway shall be deemed acceptable, irrespective of the NPRA's non-participation in the WHO CRP or the ASEAN JA evaluation.

\*\*at least one agency approval or more

## 2. ELIGIBILITY CRITERIA:

### 2.1 Abbreviated Review

#### 2.1.1 WHO Collaborative Registration Procedure (CRP)

- a) The application must be submitted via QUEST system and passed the screening stage.
- b) Manufacturing facilities have been inspected by any Pharmaceutical Inspection Cooperation Scheme (PIC/S) member with valid certification. For WHO pre-qualified medicines, valid Good Manufacturing Practice (GMP) evidence issued by WHO is acceptable.
- c) All aspects of the drug substance and drug product's quality, including but not limited to the formulation, manufacturing process, controls, site(s), release and shelf-life specifications, primary packaging and active pharmaceutical ingredient(s) source **must be identical** to that currently approved by WHO CRP at the time of submission. However, a different type of the container closure system (e.g. Alu/Alu blister vs. HDPE bottle) and pack size may be proposed to meet ASEAN stability requirements (if applicable). Any difference in the manufacturing site of the **drug product** or a difference in brand name, will be considered if it is clearly justified.
- d) If a Drug Master File (DMF) is submitted, then a separate declaration letter issued by the Product Registration Holder (PRH) must also be provided to state that the DMF submitted to NPRA is identical to that submitted to WHO CRP. DMF is not applicable for Biologics. Instead, an entire drug substance dossier will be expected.

#### 2.1.2 Products approved by the EMA and/or Health Canada and/or PMDA, Japan and/or Swissmedic, Switzerland and/or TGA, Australia and/or UK MHRA, and/or US FDA

- a) The application must be submitted to NPRA via QUEST system within three (3) years from the date of approval by the chosen reference drug regulatory agency.
- b) The PRH is required to submit a declaration statement as in Annex 1 to indicate that the assessment report, list of Question & Answer (Q & A) and all other relevant documents provided are authentic.
- c) Manufacturing facilities have been inspected by any Pharmaceutical Inspection Cooperation Scheme (PIC/S) member and have valid certification.
- d) All aspects of the drug substance and drug product's quality, including but not limited to the formulation, manufacturing process, controls, site(s), release and shelf-life specifications, primary packaging and active pharmaceutical ingredient(s) source **must be identical** to that currently approved by the chosen reference drug regulatory agency at the time of submission. However, a different type of the container closure system (e.g. Alu/Alu blister vs. HDPE bottle) and pack size may be proposed to meet ASEAN stability requirements (if applicable). Any difference in the manufacturing site of the **drug product** or a difference in brand name, will be considered if it is clearly justified.

- e) If a Drug Master File (DMF) is submitted (to specify DMF version number or ID number), then a separate declaration letter issued by the PRH must also be provided to state that the DMF submitted to NPRA is identical to that submitted to the chosen reference drug regulatory agency. DMF is not applicable for Biologics. Instead, an entire drug substance dossier will be expected.
- f) The product and its intended use (indications, dosage information, and patient groups) have not been rejected, withdrawn, suspended, approved via appeal process, or pending deferral by any reference drug regulatory agency for quality, safety and/or efficacy reasons.
- g) The proposed Package Insert (PI)/ Patient Information Leaflet (PIL) information should be identical to that approved by the reference drug regulatory agency (with the exception of country-specific information).
- h) The proposed indication(s), dosing regimen(s), patient group(s) and/or direction(s) for use should be the most stringent among those approved by the reference drug regulatory agencies. In the event that the chosen drug regulatory agency does not bear the most stringent indication(s), dosing regimen(s), patient group(s) and/or direction(s) of use among those approved by the reference drug regulatory agencies, a supplemental clinical assessment report from the reference drug regulatory agency that approved the most stringent indication(s), dosing regimen(s), patient group(s) and/or direction(s) of use is required. Reports from the public domain are acceptable. Specifically for vaccines, differences in dosage regimen are allowed when the regimen is changed to meet the local practices, such as the National Immunisation Programmes.
- i) Products which are approved/reviewed via a full evaluation process by the reference drug regulatory agency will be considered for this pathway. However, a product that has been approved under exceptional circumstances such as Conditional marketing authorisation (e.g. the present state of scientific knowledge is insufficient to provide comprehensive information) or equivalent approval process is **not eligible** for this pathway. Additionally, products requiring a more stringent assessment as a result of differences in local disease patterns and/or medical practices (e.g. some anti-infectives) will not qualify for the facilitated registration pathway.

## 2.2 Verification Review

### 2.2.1 ASEAN Joint Assessment (JA) procedure

For ASEAN JA, please refer to ASEAN Joint Assessment Procedure for Pharmaceutical Products.

## 3. DOCUMENTS REQUIRED:

The PRH is required to notify NPRA by submitting a formal, written request for a facilitated registration pathway and attaching the letter of intent under Section E14 (Other Supporting Documents) of the QUEST system. PRH is encouraged to contact the relevant section (according to product category) in NPRA prior to the submission of an application if questions arise or clarification is required.



PRH should also ensure that documents related to country specific requirements are available prior to registration submission. The requirements include but not limited to administrative data documents Stability study should comply with the ASEAN stability guideline. A minimum of 6 months real time and accelerated stability data respectively may be accepted at the point of submission. However, upon registration a minimum of 12 months for real time stability data should be provided. For generic medicines, the comparator product used for bioequivalence (BE) study should be similar to the Malaysia Comparator Product. If a BE study submitted to NPRA via the FRP pathway was conducted at a BE Centre not listed in the NPRA compliance programme or out of the NPRA validity date, the BE Study Desktop Audit application is deemed unnecessary. Evidence of the SRA's or WLA's assessment of the BE Study is required during the evaluation of the application.

### **3.1 Abbreviated Review**

#### **3.1.1 WHO Collaborative Registration Procedure (CRP)**

##### **3.1.1.1 Stringent Regulatory Authority CRP (SRA/WLA CRP)**

- a) A complete dossier organised in line with the globally harmonized common technical document (CTD) format should be submitted via the QUEST system to maximize use of data already submitted to reference SRA/WLA.
- b) In the case of generic medicines, the technical part of the dossier is equivalent to the WHO PQP prequalification dossier requirements.
- c) In addition to technical data the following documents should be provided:
  - i) expression of interest to take part in this procedure (Appendix 7)
  - ii) valid assessment and inspection reports issued by reference SRA/WLAs;
  - iii) quality information summary (QIS)-SRA(CRP) (Appendix 4);
  - iv) a declaration assuring the identity of the product with the medicine approved by the reference SRA/WLA, consent to communicate freely with the reference SRA/WLA on product-related matters, and additional commitments as specified in Appendix 7;
  - v) a declaration confirming same site and source including specific block(s) or unit(s) for active pharmaceutical ingredient (API), and finished pharmaceutical product (FPP) manufacturer;
- d) All the appendices mentioned in d (i, iii and iv) and the detailed information can be obtained from the Annex 11: Collaborative procedure in the assessment and accelerated national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities (WHO Expert Committee on Specifications for Pharmaceutical Preparations- Fifty-second report).
- e) Process flow: Please refer to **Annex 3a**

### 3.1.1.2 WHO Prequalification (PQ CRP)

- a) A complete dossier closely follows the format in which dossiers are submitted to WHO/PQP, i.e. the common technical document (CTD) format should be submitted via the QUEST system.
- b) The technical part of the dossier is updated to reflect the data as approved by WHO/PQP during the initial prequalification procedure, and consecutive variation procedures and requalification (where applicable).
- c) A dossier FRP checklist as stated in **Annex 2a for Generic/Hybrid and 2b for New Chemical Entity/Biologic**.
- d) Other than the technical data the following document should be provided:
  - Expression of interest to take part in this procedure (Appendix 3)
- e) Appendix 3 mentioned above can be obtained from the Annex 8: Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines. (WHO Expert Committee on Specifications for Pharmaceutical Preparations- Fiftieth report). Other information about the WHO PQ CRP can also be found in the same Annex.
- f) Process flow: Please refer to **Annex 3b**.

### 3.1.2 Products approved by the EMA and/or Health Canada and/or PMDA, Japan and/or Swissmedic, Switzerland and/or TGA, Australia and/or UK MHRA, and/or US FDA

#### 3.1.2.1 General technical requirements (to be submitted under the relevant field/section of the QUEST system):

- a) Complete Common Technical Document (CTD) data requirements.
- b) Complete assessment report including assessment on the Q&A documents between the PRH/Marketing Authorisation Holder and reference drug regulatory agency and all annexes (in English - to be submitted under section E14 of the QUEST system):
  - i) Assessment reports and/or documents pertaining to post-approval variations, if applicable.
  - ii) The submitted assessment reports must be unredacted or unedited, and should include details of imposed licensing conditions, final product labelling, chemistry and clinical review, and other information in relation to the product's approval. Reports obtained from the public domain are deemed unacceptable. However, NPRA may consider accepting public assessment reports with redacted information (supplemented in the same document with comments on the redacted information, whichever is known to PRH/product owner) and Q&A.

- c) A dossier FRP checklist as stated in **Annex 2a for Generic/Hybrid and 2b for New Chemical Entity/Biologic**.

**3.1.2.2 Additional administrative documents required (to be submitted under section E14 of the QUEST system).**

- a) Proof of approval from the chosen reference drug regulatory agency is required. Proof of approval must come in the form of:
  - i) an official approval letter, or equivalent document (e.g. Certificate of Pharmaceutical Product; CPP), which certifies the registration status of the drug product.
  - ii) the Summary of Product Characteristics (SPC), PI and/or PIL approved by the reference drug regulatory agency that issued the approval letter.
- b) A declaration letter issued by the product owner/PRH stating that:
  - i) all aspects of the drug substance's and drug product's quality and intended direction(s) for use, including but not limited to the formulation, manufacturing process, controls, site(s), release and shelf life specifications, primary packaging and active pharmaceutical ingredient(s) source must be **identical** to that currently approved by the chosen reference drug regulatory agency at the time of submission (including to the specification reference number, version and effective date). However, a different type of the container closure system (e.g. Alu/Alu blister vs. HDPE bottle) and pack size may be proposed to meet ASEAN stability requirements (if applicable); any difference in manufacturing site of drug product will be considered if it is clearly justified.
  - ii) the product and its intended use (indications, dosage information, and patient groups) have not been rejected, withdrawn, suspended, approved via appeal process, or pending deferral by any reference drug regulatory agency for quality, safety and/or efficacy reasons.
  - iii) the provided DMF (to specify the DMF version number or ID number) is the same as that submitted to the reference drug regulatory agency.
  - iv) there is a commitment to reference drug regulatory agency (if any).
- c) Process flow: Please refer to **Annex 3c**

### 3.2 Verification review

#### 3.2.1 ASEAN Joint Assessment (JA) Procedure

3.2.1.1 Please refer to 'ASEAN Joint Assessment Procedure for Pharmaceutical Products'.

3.2.1.2 Process flow: Please refer to **Annex 3d**.

<b>NOTE</b>
i) NPRA reserves the right to request additional supporting documents where it is deemed appropriate.
ii) Products assessed under this facilitated pathway will not be eligible for priority review.
iii) During the evaluation process, the NPRA has the right to reject the application if discrepancies are identified between the data provided and the stated declaration.

#### 4. TIMELINE FOR REGISTRATION PROCESS

Types of Review	Timeline (working days)
<b>Abbreviated Review</b>	
WHO CRP: Products authorized by WHO SRAs/WLA WHO prequalified medicines, vaccines	90*
Products approved by the EMA and/or Health Canada and/or PMDA, Japan and/or Swissmedic, Switzerland and/or TGA, Australia and/or UK MHRA, and/or the US FDA	
<b>Verification Review</b>	
ASEAN Joint Assessment	30*

\*Screening and correspondence (applicant time) are not included in the timeline.

The PRH is allowed to correspond a maximum of 3 times correspondence within the total of 60 working days. NPRA will change the FRP evaluation timeline to the standard evaluation timeline if the PRH fails to correspond within the stipulated timeline.

## **5. DRUG CONTROL AUTHORITY RIGHTS**

Notwithstanding the requirements stipulated in this guideline, DCA reserves the rights to use its own discretion whichever it deems fit.

## **6. REFERENCES**

Adapted from the:

1. WHO Good Regulatory Practices, 2021

a) Annex 8\_Collaborative procedure between the World Health Organization (WHO) Prequalification Team and national regulatory authorities in the assessment and accelerated national registration of WHO-prequalified pharmaceutical products and vaccines.

b) Annex 11\_Collaborative procedure in the assessment and accelerated national registration of pharmaceutical products and vaccines approved by stringent regulatory authorities (WHO Expert Committee on Specifications for Pharmaceutical Preparations- Fifty-second report).

2. Pan American Health Organization. Regulatory Reliance Principles: Concept note and recommendations. Ninth Conference of the Pan American Network for Drug Regulatory Harmonization (PANDRH). (San Salvador, 24 to 26 October, 2018). Washington, D.C.: PAHO; 2019.

3. ASEAN Joint Assessment Procedure for Pharmaceutical Products. [<https://asean.org/>]

**7. ANNEXES**

**7.1 Annex 1: Declaration statement by the applicant**

I \_\_\_\_\_ (I/C number: \_\_\_\_\_) on behalf of my company \_\_\_\_\_ (company no: \_\_\_\_\_) hereby confirm that the information and documents submitted in this application are true and authentic. I acknowledged that if any of the information or documents provided by me are false or misleading, I shall be guilty of an offence and shall be liable on conviction to penalties under the Sales of Drugs Act 1952, Section 12, and Regulation 8 Clause 9 under the Control of Drugs and Cosmetic Regulations 1984, respectively. I also understand that any false, misleading, or omission of information required shall render this application invalid.

Product Name :

Product Registration Holder :

Applicant name :

Designation :

Email :

Contact Number :

Signature and Date of Declaration :

## 7.2 Annex 2a: Dossier Checklist for FRP (Generic/Hybrid)

### 1. Product details

<b>Product Name</b>	
<b>Active Pharmaceutical Ingredient (API) name, strength, pharmaceutical form</b>	
<b>Product registration Holder</b>	
<b>Date of Application to NPRA</b>	
<b>Call number (QUEST)</b>	

### 2. Similarity of Data Set

<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<b>Active Pharmaceutical Ingredient (API)</b>			
<b>Name of API (1)</b>			
<b>Name and address(es) of the API manufacturer(s)</b>			

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
<b>Specification</b>  <b>Specification reference number and version</b>			
<b>Container Closure System</b>			
<b>Stability Summary and Conclusions</b>			
<b>Name of API (2):</b>			
<b>Name and address(es) of the API manufacturer(s):</b>			
<b>Specification</b>  <b>Specification reference number and version</b>			
<b>Container Closure System</b>			
<b>Stability Summary and Conclusions</b>			



<b>Finished Pharmaceutical Product (FPP)</b>			
<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<b>Description of the FPP:</b>			
<b>Composition of the FPP:</b>			
<b>Name and address of manufacturer/s of FPP</b>			
<b>The final product release if different from the manufacturer</b>			
<b>Batch formula including batch size</b>			
<b>Narrative description of the manufacturing process</b>			
<b>Control of FPP including in-process control, specifications and process validation</b>			
<b>Pack size</b>			

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
Container Closure System			
Stability Summary and Conclusions including tabulated batch numbers, stability conditions, duration of available data			
<b>Bioequivalence</b>			
Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
Study #:			
Study Title:			
Name of review committee, date of approval of protocol and consent form,			

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
Name of principal investigator			
Clinical Facility			
Clinical Laboratories			
Analytical Laboratories			
Company performing pharmacokinetic/ statistical analysis			
Overall Study Design and Plan – Description			
Test Product			
Name of reference product:			
Manufacturer of the reference product:			
DISCUSSION OF RESULTS			

### 7.3 Annex 2b: Dossier Checklist for FRP (New Chemical Entity/Biologic)

#### 1. Product details

<b>Product Name</b>	
<b>Active Pharmaceutical Ingredient (API) name, strength, pharmaceutical form</b>	
<b>Product registration Holder</b>	
<b>Date of Application to NPRA</b>	
<b>Call number (QUEST)</b>	

#### 2. Similarity of Data Set

<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<b>Active Pharmaceutical Ingredient (API)/ Drug Substance</b>			
<b>Name of API/ Drug Substance:</b>			
<b>Structural Formula</b>			
<b>Manufacturer</b>  <ul style="list-style-type: none"> <li>- Manufacturer(s)/ Site of Manufacture</li> <li>- Description of manufacturing process &amp; process controls*</li> <li>- Controls of materials*</li> </ul>			

<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<ul style="list-style-type: none"> <li>- Controls of critical steps and intermediates*</li> <li>- Process Validation and/or evaluation*</li> <li>- Manufacturing process development*</li> </ul>			
<b>Characterization</b>			
<b>Control of Drug Substance/ Specification</b>			
<b>Reference Standards &amp; Materials</b>			
<b>Container Closure System</b>			
<b>Stability Summary and Conclusions</b>			

<b>Finished Pharmaceutical Product (FPP)</b>			
<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<b>Description &amp; Composition</b>			
<b>Pharmaceutical Development</b>			
<b>Manufacturer</b>  (Name, address and responsibility)			

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
<ul style="list-style-type: none"> <li>- Batch Manufacturing Formula*</li> <li>- Manufacturing &amp; Packaging Process*</li> <li>- Control of Critical Steps &amp; Intermediates*</li> <li>- Process Validation*</li> </ul>			
<b>Control of Excipients</b>			
<p><b>Control of Finished Product</b></p> <p><b>Additional documents for Biologics*:</b></p> <ul style="list-style-type: none"> <li>- Viral Inactivation/ Removal Studies</li> <li>- Plasma Master File (Blood products only)</li> <li>- Certificate of Fitness for Purpose/ Compliance Certificate/ Plasma Quality Certificate (Blood products only)</li> <li>- Batch release certificate (for vaccines / blood products)</li> <li>- Summary Lot Protocol (for vaccines/blood products)</li> </ul>			

<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<b>Reference Standards or Materials</b>			
<b>Container Closure System</b>			
<b>Stability</b> - <b>Storage Condition, Shelf life including tabulated batch numbers, stability conditions, duration of available data</b>			
<b>Product Interchangeability / Equivalent Evidence (if any)</b>			
<b>General comments on the Product Quality</b>			

\* Please indicate the difference(s) between the data approved by the chosen reference agency or procedure and the data submitted to NPRA, if any.

**3. Comparability Data Set- for Biosimilar products only**

<b>Biosimilars</b>			
<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<b>Quality</b>			
<b>Comparability exercise</b>			
<b>Manufacturing process</b>			
<b>Reference product- Name and manufacturer (source) of reference product:</b>			
<b>Analytical/technique</b>			
<b>Characterisation</b>			
<b>Specifications</b>			
<b>Stability</b>			
<b>Non-clinical requirements</b>			
<b>In vitro studies</b>			
<b>In vivo studies</b>			



<b>Clinical requirements</b>			
<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<b>Pharmacodynamic (PK/PD) studies</b>			
Study #:			
Study Title:			
<b>Overall Study Design and Plan – Description</b>			
<b>Discussion of results</b>			
<b>Clinical efficacy trials &amp; Clinical safety and Immunogenicity</b> - Comparative efficacy and safety including potential immunogenicity			
Study #:			
Study Title:			
<b>Overall Study Design and Plan – Description</b>			
<b>Discussion of results</b>			

#### 4. Non-clinical Data

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
<p><b>Overview of the non-clinical studies</b></p> <ul style="list-style-type: none"> <li>- Pharmacology</li> <li>- Pharmacokinetics</li> <li>- Toxicology</li> </ul> <p><i>(Confirm if these are the same as approved by the reference SRA)</i></p>			
<p><b>Pivotal non-clinical safety studies</b></p> <p><i>(Confirm if these are in compliance with the OECD Principles of GLP)</i></p>			

#### 5. Clinical Data

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
<p><b>Proposed indications, dosing regimens, age groups</b></p> <p><i>(Confirm if these are the same as approved by the reference SRA)</i></p>			
<b>CLINICAL PHARMACOLOGY</b>			
<p><b>Justification for the dose / dose regimen</b> <i>(In the target population)</i></p>			

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
<b>ADME</b> <i>(Applicability in the target population)</i>			
<b>Interaction studies</b>			
<b>Pharmacodynamics</b>			
Statistical methods for additional analysis, such as subgroup analyses and adjusted analyses			
<b>BENEFIT-RISK ANALYSIS</b>			
<b>Relevance of studied population for the target population (e.g. ethnicity, gender representation, age groups) as regards to demonstration of safety and efficacy</b>			
<b>Relevance of SRA-approved conditions of use (proposed indications, dose and directions of use) as regards to epidemiology and disease pattern in the target countries as well as other implications for efficacy and safety, e.g. feasibility of monitoring and precautionary measures (e.g. resistance testing or therapeutic drug monitoring)</b>			


<b>Item</b>	<b>Data approved by the chosen reference agency or procedure</b>	<b>Data submitted to NPRA</b>	<b>Comments</b>
<b>The adequacy of the directions for use</b>			
<b>Therapeutic role of a product and its recommended use according to relevant national and international treatment guidelines</b>			
<b>Other related quality issues, including but not limited to, storage conditions and conditions of administration and use (if any).</b>			
<b>GENERAL COMMENTS ON CLINICAL DATA</b>			

## 6. Risk Management Plans

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
<b>Risk management plan (RMP) was provided with the submission?</b>			
<b>Epidemiology of the indications and target population</b> Relevance of the clinical trial population to the intended target population (inclusions, exclusions, limited numbers, trial setting, use in special populations).			
<b>Assessment of identified and potential risks</b> Inclusion of all important risks related to the active substance, formulation, route of administration, target population, specific sub-populations and the potential for interaction from the safety specifications			
<b>Summary of planned pharmacovigilance activities (including post-authorisation safety studies)</b> On-going and planned studies in the Post-authorisation Pharmacovigilance Development Plan in the target population			

Item	Data approved by the chosen reference agency or procedure	Data submitted to NPRA	Comments
Plans for post-authorisation efficacy studies (if applicable)			
Risk minimization measures			
<p><b>Summary of the risk management plan</b></p> <p>General comments on the RMP</p>			


## 7.4 Annex 3a: Process Flowchart for WHO SRA/WLA CRP



### Notes:

- (a) PRH to express interest applying this procedure with NPRA by email. PRH to provide the reference SRA/WLA its consent (Appendix 3A) to share its regulatory information with NPRA. PRH to request a valid assessment and inspection report from the respective reference SRA/WLA (if not yet available) and to request permission for sharing the assessment and inspection report from the respective reference SRA/WLA (Appendix 3B). PRH prepares the quality information summary (QIS) reference SRA/WLA (QIS-SRA (CRP)) (Appendix 4) and the QIS should be verified and endorsed by the reference SRA/WLA that issued the marketing authorization.
- (b) PRH is strongly recommended to upload documents as per CTD format in QUEST system within 90 days from the receipt date of documentations from the reference SRA/WLA.
- (c) NPRA validates the applications and documents and informs the PRH of its decision whether to apply or not within 30 days. PRH will make payment if the application is acceptable or eligible for FRP.
- (d) NPRA communicates with PRH for additional data (if necessary).
- (e) NPRA communicates with reference SRA/WLA for confirmation of the authenticity or validity of any of the assessment or inspection reports submitted (if necessary)
- (f) Manufacturer to notify WHO (Appendix 9) after granting the registration decision by this procedure.

## 7.5 Annex 3b: Process Flowchart for WHO PQ CRP




**Notes:**

- (a) PRH to express interest of this procedure by emailing to the respective section (Appendix 3, Part A). The same form is also submitted to WHO/PQT.
- (b) PRH to submit dossier for screening as per ACTD format via the QUEST system.
- (c) NPRA informs the decision to applicant and WHO/ PQT (accepted as complete or refusal. (Appendix 3, Part B)
- (d) WHO/ PQT provides NPRA with the product-related information and documentation through restricted-access website.
- (e) NPRA communicates with PRH for additional data (if necessary).
- (f) NPRA communicates with WHO/ PQT for additional explanations (if necessary)
- (g) NPRA to notify WHO/ PQT and the PRH (Appendix 3, Part C) after DCA's decision and indication(s).



**7.6 Annex 3c: Process Flowchart for Products approved by the EMA and/or Health Canada and/or PMDA, Japan and/or Swissmedic, Switzerland and/or TGA, Australia and/or UK MHRA, and/or US FDA**



7.7 Annex 3d: Process Flowchart for ASEAN Joint Assessment

